Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EtopoTax Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer
NCT00033696Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2001
- Primary completion
- Jan 2007
- Countries
- 1
- Sponsor
- Cancer and Leukemia Group B
- Modality
- Small Molecules
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, topotecan and etoposide in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Response Rate up to 5 years. Started Sep 2001; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
chemotherapy + radiation therapy
Induction with Paclitaxel/Topotecan/Etoposide followed by Consolidation with Carboplatin/Etoposide + RT
03
Who it enrols
Patients with histologically confirmed limited-stage small cell lung cancer, measurable disease, ECOG PS 0-2, and adequate organ function. No prior chemotherapy or chest radiotherapy.
04
Endpoints
Primary
Overall Response Rate
Secondary
Failure-Free Survival
Overall Survival
Toxicity
Beyond the preview
Go deeper on NCT00033696.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033696.